Scientific

Board

Prof. Michael Belkin

Dr. Ophthalmology, Prof. Emeritus, Sheeba Hospital, Israel

Prof. Belkin received an M.A. degree in Science from Cambridge University, England, and an M.D. degree in Medicine from the Hebrew University of Jerusalem, Israel. He is the author of over 250 scientific publications and holds over 25 patents.

Prof Belkin established and was the first full-time director of the Tel Aviv University Goldshlager Eye Research Institute. He was also:

Head of the pediatric ophthalmology services at Hadassah University Hospital and the Sheba Medical Center

  • Chairman of the Tel Aviv University Department of Ophthalmology
  • President of the Israel Society of Eye and Vision Research of which he was a co-founder
  • Chairman, Permanent Advisory Committee in Ophthalmology, Ministry of Health.
  • Incumbent of the Tel Aviv University Sidney A. Fox Chair of Ophthalmology
  • Chairman, Ophthalmology Committee, National Councils for Health
  • Chairman, Commercial Relationship Committee, Association for Research in Vision and Ophthalmology (ARVO)
  • Head of the Research and Development branch of the Israeli military medical department

Dr. Liat Lomnitski

VP. Regulation & Pre-clinical studies. Padagis, Israel

Dr. Liat Lomnitski is one of the known Israeli experts in Preclinical studies, Safety, Toxicology, and Regulation. With vast experience in the pharma industry and 18 years with Perrigo/Padagis, she brings tremendous expertise and knowledge to the board of the company.  In addition, Dr. Lomnitski is a member of the scientific advisory board of CanNegev Incubator.

Dr. Lomnitski received her PhD in Biochemistry from Bar-Ilan University and postdoctoral studies in Neuroscience from Tel-Aviv University

Prof. David Stepensky

Head of School of Pharmacy, Ben Gurion University. Israel

Dr. David Stepensky is an Associate Professor from the Department of Clinical Biochemistry and Pharmacology, Ben-Gurion University of the Negev, Beer-Sheva, Israel. He holds PhD degree from the Dept. of Pharmaceutics, School of Pharmacy, The Hebrew University of Jerusalem, Israel, and received post-doctoral training at the Dept. of Immunology, Weizmann Institute of Sciences, Rehovot, Israel and at the Dept. of Immunobiology, Yale University, New Haven, CT, USA. His primary research interests are analysis of pharmacokinetic and pharmacodynamic properties of pharmacological agents (small molecular weight drugs and biopharmaceuticals) and development of nanovesicle- and nanoparticle-based systems that can efficiently deliver these agents to their site of action. He authors over 50 papers and book chapters, serves as consultant to the Israeli Ministry of Health, pharmaceutical and start-up companies, and delivers customized workshops and courses on drug development, pharmaceutics, pharmacology and other topics of his research expertise.

Dana Rubin

Dana Rubin

USA Cannabis Regulation

Dana is a leading expert in pharmaceutical and cannabis biotechnology. Her company, PharmaConsult LTD advises companies on regulatory guidance, FDA compliance, and product formulation. Her past experience includes working with a generic pharmaceutical company that has a pipeline of FDA targeted products (totaling over 1B+ in brand sales) and licensing partnerships with leading multibillion-dollar pharmaceutical companies.

Dana is an alumni of California State University, Chapman University’s George L. Argyros School of Business and Economics, and is currently attending the University of Maryland, School of Pharmacy for a Master’s of Science in Medical Cannabis and Therapeutics.

Skip to content